We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+34.4%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$3.43B
AUM Growth
+$283M
Cap. Flow
-$809M
Cap. Flow %
-23.57%
Top 10 Hldgs %
38.81%
Holding
112
New
24
Increased
11
Reduced
35
Closed
19

Top Buys

Rank Stock Value
1
HOLX
Hologic
HOLX
+$67.2M
2
LRMR icon
Larimar Therapeutics
LRMR
+$59.9M
3
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$29.8M
4
GBIO
Generation Bio
GBIO
+$26.4M
5
RNAM
Avidity Biosciences
RNAM
+$25.3M

Top Sells

Rank Stock Value
1
AHCO icon
AdaptHealth
AHCO
+$264M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$168M
3
QTTB icon
Q32 Bio
QTTB
+$62.7M
4
ABMD
Abiomed Inc
ABMD
+$54.6M
5
IMMU
Immunomedics Inc
IMMU
+$45.2M

Sector Composition

Rank Sector Weight
1 Healthcare 65.56%
2 Financials 0.55%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVEO
76
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$1.84M 0.05%
+357,101
New +$2.25M
RCKT icon
77
Rocket Pharmaceuticals
RCKT
$361M
$1.11M 0.03%
53,043
-1,624,324
-97% -$29.3M
ELGX
78
DELISTED
Endologix Inc
ELGX
$764K 0.02%
950,000
– –
NEOS
79
DELISTED
Neos Therapeutics, Inc
NEOS
$220K 0.01%
320,993
– –
WINT
80
DELISTED
Windtree Therapeutics
WINT
– –
0
– –
ARGX icon
81
argenx
ARGX
$56.4B
– –
-151,779
Closed -$20M
AXGN icon
82
Axogen
AXGN
$2.18B
– –
-937,983
Closed -$9.76M
DXCM icon
83
DexCom
DXCM
$28.4B
– –
-348,000
Closed -$23.4M
KRRO icon
84
Korro Bio
KRRO
$152M
– –
-18,914
Closed -$16.8M
PASG icon
85
Passage Bio
PASG
$15.3M
– –
-33,518
Closed -$10.6M
PBYI icon
86
Puma Biotechnology
PBYI
$408M
– –
-963,212
Closed -$8.13M
SRPT icon
87
Sarepta Therapeutics
SRPT
$1.72B
– –
-235,000
Closed -$23M
SYBX
88
DELISTED
Synlogic
SYBX
– –
-25,353
Closed -$654K
TNDM icon
89
Tandem Diabetes Care
TNDM
$1.14B
– –
-412,867
Closed -$26.6M
TPST icon
90
Tempest Therapeutics
TPST
$15.2M
– –
-866
Closed -$892K
UHS icon
91
Universal Health Services
UHS
$9.73B
– –
-138,874
Closed -$13.8M
ZVRA icon
92
Zevra Therapeutics
ZVRA
$569M
– –
-26,163
Closed -$94K
QTTB icon
93
Q32 Bio
QTTB
$452M
– –
-224,295
Closed -$62.7M
TECX
94
Tectonic Therapeutic
TECX
$582M
– –
-93,740
Closed -$17.5M
SYRS
95
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-126,895
Closed -$7.53M
HARP
96
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
– –
-16,764
Closed -$1.94M
ABMD
97
DELISTED
Abiomed Inc
ABMD
– –
-376,000
Closed -$54.6M
CHNG
98
DELISTED
Change Healthcare Inc. Common Stock
CHNG
– –
-214,789
Closed -$2.15M
FTSV
99
DELISTED
Forty Seven, Inc. Common Stock
FTSV
– –
-155,380
Closed -$14.8M
1 2 3
4

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q2 2020 Portfolio in Review

As of Q2 2020, Deerfield Management held 112 positions worth $3.43B, up 9% from $3.15B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Deerfield Management withdrew a net $809M in Q2 2020, closing 19 positions and reducing 35 holdings. Its most notable exit was Q32 Bio, an estimated $62.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 72% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in Hologic worth $78.1M.

  • Deerfield Management's largest Q2 2020 buy was Hologic: 1,370,186 shares worth $78.1M.
  • Deerfield Management added most to MyoKardia, Inc. Common Stock in Q2 2020, an estimated $29.8M increase.
  • Deerfield Management's biggest Q2 2020 reduction was AdaptHealth, cutting an estimated $264M.
  • Deerfield Management fully exited Q32 Bio in Q2 2020, selling an estimated $62.7M.
  • Deerfield Management's ten largest holdings make up 39% of its $3.43B portfolio in Q2 2020.
  • Deerfield Management opened 24 new positions and closed 19 in Q2 2020.
  • Deerfield Management's portfolio value rose 9% quarter-over-quarter to $3.43B.

Based on Deerfield Management's 13F filing for Q2 2020, filed 14 Aug 2020.